News

Physician details her journey from sustaining career-ending injury to insurance advocate.

CorNeat Vision is among the many companies working to try to maintain operations amid the conflict.

Eyecare providers report slower Q3 and increased concern for the US economy and inflation rates.

Orbis advances cataract surgery training in low-resource areas with technology

Flinders University Ophthalmologists have devised a novel glaucoma polygenic risk score (PRS) that identifies those at high risk of losing their sight and prioritizes their treatment.

A study of the course was conducted in Vietnam, and showed participant scores doubled following the online course, to a level like local ophthalmologists.

Mohammed Genead, MD, CEO of Aviceda spoke with the Ophthalmology Times team about the company's Phase II/III SIGLEC trial part 1 results, which were shared at this year's American Academy of Ophthalmology meeting.

Rob Thornhill, CEO of Centricity Vision spoke with the Ophthalmology Times team about the company's newest developments at this year's American Academy of Ophthalmology meeting.

The Kingfisher Study found that the visual outcomes after 1 year of brolucizumab, 6 mg, (Beovu, Novartis) in participants with diabetic macular edema (DME) did not differ significantly from those obtained with aflibercept

Marco A. Zarbin, MD, spoke with the Ophthalmology Times team about conducting a post-hoc analysis of the YOSEMITE and RHINE clinical trials and presenting the results at this year's American Academy of Ophthalmology meeting.

Slit lamp evaluation can provide valuable information for treatment course.

The aim of the MBCT was possibly re-training patient brains to remove their static-type images.

Michael Rivers, MD, Senior Director of Ophthalmology at ModMed spoke with Modern Retina about their new single-screen initiative and the benefits it could have for saving time and simplifying communication within practices.

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept at this year's American Academy of Ophthalmology meeting.

In the study, researchers changed the microenvironment in the eye in a way that enabled them to take stem cells from blood and turn them into retinal ganglion cells that were capable of migrating and surviving into the eye’s retina.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss a novel mitochondrial mutation found in a case of isolated LHON (Leber hereditary optic neuropathy).

Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint in the clinical trial.

Ophthalmic data are well suited to the demands of regulatory-grade use cases.

The company also completes enrollment of the multiple ascending dose phase of AMARONE, the first clinical trial of EyeBio’s lead investigational asset Restoret, with favorable initial safety and tolerability at all dose levels.

Community-based eye care is one of Orbis’s top priorities in the country.

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualization and patients who've had small aperture IOL implantation at this year's American Academy of Ophthalmology meeting.

According to the companies, the merger creates a NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics’ lead assets for the treatment of presbyopia.

Loretta Alborghetti, from Redditch, UK, a medical secretary within the ophthalmology department at Worcestershire Acute Hospitals NHS Trust, illegally accessed the records of more than 150 patients.

Charles Wykoff, MD, PhD, spoke with Ophthalmology Times about the GALE study data at one year looking at pegcetacoplan for the management of geographic atrophy at this year's American Academy of Ophthalmology meeting.

Approach to lowering IOP reduces medication burden without risking graft rejection.

Researchers found reduced iron concentration in the clear gel part of the eye of human patients and iron accumulation in the retina of mice.

The improvement of accessibility and education could drive changes in outcomes.